imatinib
novartis
['imatinib', '#gi']
continuous versus intermittent dosing of #imatinib re-challenge in #gist patients. patients were randomized into two groups: intermittent dosing and continuous dosing. survival outcomes showed similar median times for progression-free survival and overall survival.
#asco2022 
Enhancing survival and quality of life for people living with GIST through patient-powered research, education and empowerment, and global advocacy efforts.